Deutsche Bank AG Has $1.66 Million Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)

Deutsche Bank AG raised its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 25.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 327,900 shares of the biopharmaceutical company's stock after buying an additional 66,253 shares during the quarter. Deutsche Bank AG owned about 0.14% of Ardelyx worth $1,662,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Swiss National Bank grew its stake in Ardelyx by 1.0% during the 4th quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company's stock worth $2,348,000 after buying an additional 4,800 shares during the last quarter. Orion Portfolio Solutions LLC boosted its stake in Ardelyx by 42.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company's stock valued at $84,000 after buying an additional 4,933 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Ardelyx by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 50,222 shares of the biopharmaceutical company's stock worth $255,000 after purchasing an additional 4,942 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Ardelyx by 1.9% in the 4th quarter. Rhumbline Advisers now owns 326,124 shares of the biopharmaceutical company's stock worth $1,653,000 after acquiring an additional 6,070 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of Ardelyx by 101.8% in the 4th quarter. KBC Group NV now owns 13,706 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 6,915 shares in the last quarter. 58.92% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ARDX has been the subject of several research reports. Scotiabank began coverage on shares of Ardelyx in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Raymond James downgraded shares of Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 price target on the stock. in a report on Friday, May 2nd. Piper Sandler upgraded shares of Ardelyx to a "hold" rating in a report on Wednesday, March 12th. Citigroup decreased their price target on Ardelyx from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen cut Ardelyx from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.39.

Insider Activity at Ardelyx

In other Ardelyx news, insider Mike Kelliher sold 14,522 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $59,249.76. Following the sale, the insider now owns 282,158 shares of the company's stock, valued at $1,151,204.64. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Laura A. Williams sold 6,421 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total transaction of $26,197.68. Following the completion of the transaction, the insider now owns 402,583 shares of the company's stock, valued at $1,642,538.64. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 208,477 shares of company stock valued at $932,254 over the last quarter. 4.80% of the stock is owned by company insiders.

Ardelyx Stock Performance

Shares of ARDX stock traded up $0.12 during trading hours on Thursday, reaching $4.03. 3,391,061 shares of the company's stock were exchanged, compared to its average volume of 4,441,301. Ardelyx, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $8.06. The business has a fifty day moving average price of $4.42 and a 200-day moving average price of $4.99. The stock has a market capitalization of $964.20 million, a P/E ratio of -25.19 and a beta of 0.76. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The firm had revenue of $74.11 million during the quarter, compared to analyst estimates of $79.40 million. During the same period last year, the company earned ($0.11) EPS. The company's revenue was up 61.1% on a year-over-year basis. Analysts predict that Ardelyx, Inc. will post -0.18 EPS for the current fiscal year.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.